Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSolvonis Therap Regulatory News (SVNS)

Share Price Information for Solvonis Therap (SVNS)

Share Price is delayed by 15 minutes
Get Live Data
0.215    -0.001 (-0.47%)
Bid:
0.21
Ask:
0.22
Spread: 0.01 (4.762%)
Market Cap: £14.36m
SVNS Live PriceLast checked at - London Stock Exchange

Intraday Solvonis Therap Share Chart

Interview with CEO

15 Jan 2025 07:00

RNS Number : 3342T
Solvonis Therapeutics PLC
15 January 2025
 

RNS Reach - non-regulatory announcement

15 January 2025

Solvonis Therapeutics plc("Solvonis Therapeutics" or the "Company")

 

Proactive Investors interview with CEO

 

Solvonis Therapeutics (LON: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, announces an interview on Proactive Investors with Anthony Tennyson, CEO of the Company. The interview with Anthony Tennyson can we viewed now at https://www.proactiveinvestors.co.uk/companies/news/1064271/solvonis-therapeutics-ceo-on-name-change-awakn-acquisition-and-2025-priorities.html.

 

Enquiries:

 

Solvonis Therapeutics plcAnthony Tennyson, CEO & Executive DirectorEmail: anthonytennyson@graftpolymer.co.uk and also anthony@solvonis.com

 

Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Solvonis Therapeutics plc

 

Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders.  Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the US, UK and key EU markets.

 

For more information, please visit www.graft polymer.co.uk and also www.solvonis.com

 

About Reach announcements

This is an RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGPUGPGUPAPUC
12
Date   Source Headline
27th May 202612:00 pmRNSNotice of Annual General Meeting
5th May 20267:00 amRNS-RCSO Speaks at National Research Meeting
29th Apr 20267:00 amRNSFinal Results
22nd Apr 20267:00 amRNS-RAppointment of Water Tower Research
20th Apr 20268:32 amRNS-RUS CNS Executive Order
8th Apr 20267:00 amRNSGranted U.S. Patent from PTSD Discovery Programme
31st Mar 20267:00 amRNSGranted U.S. Patent from PTSD Discovery Programme
10th Mar 20267:00 amRNSSVN-114 selected for PTSD discovery programme
28th Jan 20267:00 amRNSExpansion of SVN-015 into depression
7th Jan 20267:00 amRNSUS Patent allowance for PTSD discovery programme
22nd Dec 20257:00 amRNSResearch and Development Update - Q4 2025
22nd Dec 20257:00 amRNSResearch and Development Update – Q4 2025
3rd Dec 20257:00 amRNSSVN-015 accepted into US NIDA funded programme
31st Oct 20253:59 pmRNSTotal Voting Rights
31st Oct 20257:00 amRNSCorporate Structure Update and Issue of Options
27th Oct 20257:00 amRNSAppoints global biopharma leader Paul Carter
16th Oct 20257:00 amRNSRaises £1.25 Million to Accelerate Programmes
30th Sep 20257:00 amRNSHalf-year Report
28th Aug 20257:00 amRNSSolvonis secures exclusive CNS collaboration
13th Aug 20253:03 pmRNS-RMedia Coverage: Small Cap Idea profile
12th Aug 20257:00 amRNSSVN-SDN-14 PTSD - Positive pre-clinical results
31st Jul 20254:30 pmRNSTotal Voting Rights
22nd Jul 20257:00 amRNSTranslational Bridging Studies
18th Jul 202511:03 amRNSExercise of warrants
14th Jul 20257:00 amRNS-RSolvonis Chair to speak at Lucid Capital Markets
11th Jul 20257:00 amRNS£1m subscription to accelerate AI drug discovery
8th Jul 20257:00 amRNSHolding(s) in Company
27th Jun 20252:38 pmRNSAGM Statement
27th Jun 20258:54 amRNSHolding(s) in Company
26th Jun 202510:21 amRNS-RInitiation of Research Coverage
23rd Jun 20257:00 amRNSAllowance of U.S. patent covering AI-supported CNS
11th Jun 20257:30 amRNSInitiation of AI supported CNS drug discovery
5th Jun 20257:00 amRNSSynthesis of development candidate for SVN-SDN-014
3rd Jun 20254:30 pmRNSNotice of Annual General Meeting
3rd Jun 20257:00 amRNSAppointment of Prof. David Nutt as CSO
2nd Jun 202511:58 amRNSHolding(s) in Company
30th May 20255:00 pmRNSTotal Voting Rights
29th May 20253:11 pmRNSHolding(s) in Company
29th May 202512:02 pmRNSHolding(s) in Company
29th May 202510:30 amRNSHolding(s) in Company
29th May 20257:00 amRNS-RPresentation at Mello2025
28th May 20257:30 amRNSHolding(s) in Company
28th May 20257:00 amRNSCompletion of the acquisition of Awakn
21st May 20253:24 pmRNSPublication of a Prospectus
16th May 20257:31 amRNSResult of placing
15th May 20254:53 pmRNSProposed equity fundraising via ABB
28th Apr 202511:30 amRNSResult of General Meeting
23rd Apr 20257:00 amRNSProposed acquisition of Awakn approved
16th Apr 20257:00 amRNSFinal Results for the year ended 31 December 2024
10th Apr 20252:00 pmRNSPosting of Circular and Notice of General Meeting
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.